- Home
- SOBR vs VIVS Comparison
SOBR vs VIVS Comparison
Compare SOBR & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOBR
- VIVS
- Stock Information
- Founded
- SOBR 2004
- VIVS 2007
- Country
- SOBR United States
- VIVS United States
- Employees
- SOBR N/A
- VIVS N/A
- Industry
- SOBR Newspapers/Magazines
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOBR Consumer Discretionary
- VIVS Health Care
- Exchange
- SOBR Nasdaq
- VIVS Nasdaq
- Market Cap
- SOBR 4.9M
- VIVS 4.7M
- IPO Year
- SOBR N/A
- VIVS N/A
- Fundamental
- Price
- SOBR $3.24
- VIVS $3.80
- Analyst Decision
- SOBR
- VIVS
- Analyst Count
- SOBR 0
- VIVS 0
- Target Price
- SOBR N/A
- VIVS N/A
- AVG Volume (30 Days)
- SOBR 14.7K
- VIVS 868.7K
- Earning Date
- SOBR 11-13-2025
- VIVS 11-07-2025
- Dividend Yield
- SOBR N/A
- VIVS N/A
- EPS Growth
- SOBR N/A
- VIVS N/A
- EPS
- SOBR N/A
- VIVS N/A
- Revenue
- SOBR $301,400.00
- VIVS $142,000.00
- Revenue This Year
- SOBR N/A
- VIVS $42.38
- Revenue Next Year
- SOBR N/A
- VIVS $15.42
- P/E Ratio
- SOBR N/A
- VIVS N/A
- Revenue Growth
- SOBR 73.21
- VIVS 94.52
- 52 Week Low
- SOBR $2.41
- VIVS $1.41
- 52 Week High
- SOBR $193.50
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- SOBR 44.82
- VIVS 63.52
- Support Level
- SOBR $3.08
- VIVS $3.29
- Resistance Level
- SOBR $3.31
- VIVS $5.30
- Average True Range (ATR)
- SOBR 0.20
- VIVS 0.63
- MACD
- SOBR 0.01
- VIVS 0.12
- Stochastic Oscillator
- SOBR 51.18
- VIVS 56.48
About SOBR SOBR Safe Inc.
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.